Literature DB >> 25690678

Identification of the PRMT1v1 and PRMT1v2 specific interactomes by quantitative mass spectrometry in breast cancer cells.

R Mitchell Baldwin1,2, Margaret Bejide1,2, Laura Trinkle-Mulcahy1,2, Jocelyn Côté1,2.   

Abstract

Arginine methylation is catalyzed by a family of enzymes called protein arginine methyltransferases (PRMTs). The PRMT1 gene generates at least seven distinct alternatively spliced isoforms (PRMT v1-v7), which together contribute a significant portion of the cellular arginine methylome. The distinct biochemical and biological functions of these PRMT1 isoforms have not been well characterized. Previously we have shown that while both PRMT1v1 and PRMT1v2 are overexpressed in breast cancer cells, PRMT1v2 specifically promotes breast cancer cell survival and invasion. These isoforms also have distinct subcellular localizations, PRMT1v1 is mainly nuclear and PRMT1v2 cytosolic. To gain further knowledge into their isoform-specific roles within cells we used a SILAC-based quantitative affinity purification/MS approach to identify their individual protein interactomes in breast cancer cells. This analysis has uncovered distinct interactomes for PRMT1v1 and PRMT1v2. Consistent with their distinct subcellular localizations, PRMT1v1 enriched a mainly nuclear protein interactome, while PRMT1v2 enriched predominantly cytoplasmic interactors from whole-cell extracts. Furthermore, these interactomes revealed that PRMT1v1 has a role in regulating gene expression, while PRMT1v2 functions in cytoskeletal dynamics. These results highlight the unique functions of these isoforms and the distinct roles they may play within cells, with potential implications for breast cancer and other diseases.
© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Arginine methylation; Breast cancer; PRMT; Quantitative mass spectrometry; SILAC

Mesh:

Substances:

Year:  2015        PMID: 25690678     DOI: 10.1002/pmic.201400209

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  7 in total

1.  Protein arginine methyltransferase 1 promoted the growth and migration of cancer cells in esophageal squamous cell carcinoma.

Authors:  Weizheng Zhou; Hui Yue; Chunguang Li; Hezhong Chen; Yang Yuan
Journal:  Tumour Biol       Date:  2015-09-22

2.  PRMT1 expression predicts sensitivity to platinum-based chemotherapy in patients with ovarian serous carcinoma.

Authors:  Hiroaki Matsubara; Takeshi Fukuda; Yuichiro Awazu; Shigenori Nanno; Masahiro Shimomura; Yuta Inoue; Makoto Yamauchi; Tomoyo Yasui; Toshiyuki Sumi
Journal:  Oncol Lett       Date:  2020-12-31       Impact factor: 2.967

Review 3.  Proteomics-Based Analysis of Protein Complexes in Pluripotent Stem Cells and Cancer Biology.

Authors:  Putty-Reddy Sudhir; Chung-Hsuan Chen
Journal:  Int J Mol Sci       Date:  2016-03-22       Impact factor: 5.923

Review 4.  Protein arginine methylation: an emerging regulator of the cell cycle.

Authors:  Anita E Raposo; Sabine C Piller
Journal:  Cell Div       Date:  2018-03-20       Impact factor: 5.130

5.  PRMT1 regulates the tumour-initiating properties of esophageal squamous cell carcinoma through histone H4 arginine methylation coupled with transcriptional activation.

Authors:  Yue Zhao; Qijue Lu; Chunguang Li; Xinyu Wang; Long Jiang; Lei Huang; Chao Wang; Hezhong Chen
Journal:  Cell Death Dis       Date:  2019-05-01       Impact factor: 8.469

6.  PRMT7 methylates eukaryotic translation initiation factor 2α and regulates its role in stress granule formation.

Authors:  Nasim Haghandish; R Mitchell Baldwin; Alan Morettin; Haben Tesfu Dawit; Hemanta Adhikary; Jean-Yves Masson; Rachid Mazroui; Laura Trinkle-Mulcahy; Jocelyn Côté
Journal:  Mol Biol Cell       Date:  2019-01-30       Impact factor: 4.138

7.  In Vitro and In Vivo Study on the Effect of Lysosome-associated Protein Transmembrane 4 Beta on the Progression of Breast Cancer.

Authors:  Deyou Tao; Junqing Liang; Yihong Pan; Yanting Zhou; Ying Feng; Lin Zhang; Jingjing Xu; Hui Wang; Ping He; Jie Yao; Yang Zhao; Qinjie Ning; Wen Wang; Wei Jiang; Jing Zheng; Xia Wu
Journal:  J Breast Cancer       Date:  2019-09-27       Impact factor: 3.588

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.